文献速递心力衰竭与心肌病心律失常

巨细胞心肌炎的管理:JACC 本周综述

Management of Patients With Giant Cell Myocarditis: JACC Review Topic of the Week.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

巨细胞心肌炎是一种由T细胞介导的罕见、快速进展且可能致命的心肌炎症,常表现为急性心衰、心源性休克、难治性室性心律失常和/或心脏传导阻滞。诊断需心内膜心肌活检,联合免疫抑制治疗与指南导向药物治疗已改善总体生存和无移植生存。

要点

  • 巨细胞心肌炎常表现为急性心衰、心源性休克、难治性室性心律失常或心脏传导阻滞。
  • 心内膜心肌活检是确诊巨细胞心肌炎的必需检查。
  • 联合免疫抑制治疗加指南导向药物治疗可改善总体生存和无移植生存。

核心结论

  • 联合免疫抑制治疗与指南导向药物治疗已使巨细胞心肌炎管理发生范式转变,改善总体生存和无移植生存。

研究设计与样本

  • JACC 本周综述,总结巨细胞心肌炎的诊断与管理。

主要发现

  • 巨细胞心肌炎通常影响年轻和中年成人,病程常表现为急性心衰、心源性休克、难治性室性心律失常和/或心脏传导阻滞。
  • 心脏生物标志物和多模态影像常用于初始诊断检查,但确诊需心内膜心肌活检。
  • 早期诊断和及时管理可降低移植或死亡风险,而心源性休克患者中移植或死亡仍常见。

临床怎么用

  • 对疑似巨细胞心肌炎患者应尽早行心内膜心肌活检以确诊。
  • 确诊后应联合免疫抑制治疗与指南导向药物治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Giant cell myocarditis is a rare, often rapidly progressive and potentially fatal, disease due to T-cell lymphocyte-mediated inflammation of the myocardium that typically affects young and middle-aged adults. Frequently, the disease course is marked by acute heart failure, cardiogenic shock, intractable ventricular arrhythmias, and/or heart block. Diagnosis is often difficult due to its varied clinical presentation and overlap with other cardiovascular conditions. Although cardiac biomarkers and multimodality imaging are often used as initial diagnostic tests, endomyocardial biopsy is required for definitive diagnosis. Combination immunosuppressive therapy, along with guideline-directed medical therapy, has led to a paradigm shift in the management of giant cell myocarditis resulting in an improvement in overall and transplant-free survival. Early diagnosis and prompt management can decrease the risk of transplantation or death, which remain common in patients who present with cardiogenic shock.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Bang V, Ganatra S, Shah SP, et al. Management of Patients With Giant Cell Myocarditis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021. PMID: 33632487. doi:10.1016/j.jacc.2020.11.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。